Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1996 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults.
Bassan R, Lerede T, Barbui T. Bassan R, et al. Haematologica. 1996 Jan-Feb;81(1):20-36. Haematologica. 1996. PMID: 8900848 Review.
Bone marrow recurrence of adult acute lymphoblastic leukemia is typically an aggressive and most often rapidly fatal condition, an ideal setting for testing the latest research developments and experimental therapeutic options. ...Choice of retreatment …
Bone marrow recurrence of adult acute lymphoblastic leukemia is typically an aggressive and most often rapidly fatal co …
Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond.
Park J. Park J. J Natl Compr Canc Netw. 2019 Nov;17(11.5):1448-1450. doi: 10.6004/jnccn.2019.5030. J Natl Compr Canc Netw. 2019. PMID: 31766014
Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of …
Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved …
Treatment of acute lymphoblastic leukemia in relapse: efficacy of a four-drug reinduction regimen.
Poplack DG, Reaman GH, Wesley R. Poplack DG, et al. Cancer Treat Rep. 1981;65 Suppl 4:93-6. Cancer Treat Rep. 1981. PMID: 6955015
The experience of 47 similarly-treated patients with acute lymphoblastic leukemia who developed hematologic relapse was reviewed to determine the effectiveness of reinduction therapy. ...These encouraging results underscore the efficacy of the four-dru …
The experience of 47 similarly-treated patients with acute lymphoblastic leukemia who developed hematologic relapse was …